Abstract
The heritability of major depression has been documented in a number of epidemiologic studies. Twin studies have estimated the heritability at about 37% and these estimation can rise up to 70% if severity, relapse rate and age of onset are considered. Despite the relative importance of genetic risk factors in the pathogenesis of this disease, molecular genetic studies, including large genome-wide association studies, only a very small number of candidate genes, explaining little of the variance have been identified. This fact has been termed “missing heritability” and could be accounted by a number of factors including that the presumed causal variants are not tagged by the current genetic approaches, that major depression is truly polygenic, with each polymorphism only contributing very small increases in risk, unaccounted environmental influences and complex epigenetic factors. Epigenetics refers to the regulation of DNA transcription without alteration of the original sequence and is controlled by DNA methylation, histone modifications and non-coding RNAs and can be transmitted through generations. A number of clinical and preclinical studies suggest that epigenetic mechanisms could play an important role in the pathogenesis and treatment of major depression. So far, most studies investigated genes within the hypothalamicpituitary- adrenal (HPA) axis or the neurotrophin system. It is also of interest that current psychopharmacologic drugs including antidepressants, antipsychotics and mood stabilizers may exert some of their effects by inducing epigenetic changes. Most notably, epigenetic alterations are potentially reversible and accessibe for drug treatment, which lead to the development of novel classes of antidepressant drugs.
Keywords: Major depression, gene, epigenetic, GWAS, antidepressant missing heritability, SNP, HPA-axis, relapse rate, age of onset, neurotrophin system
Current Pharmaceutical Design
Title:Epigenetics, Depression and Antidepressant Treatment
Volume: 18 Issue: 36
Author(s): Andreas Menke, Torsten Klengel and Elisabeth B. Binder
Affiliation:
Keywords: Major depression, gene, epigenetic, GWAS, antidepressant missing heritability, SNP, HPA-axis, relapse rate, age of onset, neurotrophin system
Abstract: The heritability of major depression has been documented in a number of epidemiologic studies. Twin studies have estimated the heritability at about 37% and these estimation can rise up to 70% if severity, relapse rate and age of onset are considered. Despite the relative importance of genetic risk factors in the pathogenesis of this disease, molecular genetic studies, including large genome-wide association studies, only a very small number of candidate genes, explaining little of the variance have been identified. This fact has been termed “missing heritability” and could be accounted by a number of factors including that the presumed causal variants are not tagged by the current genetic approaches, that major depression is truly polygenic, with each polymorphism only contributing very small increases in risk, unaccounted environmental influences and complex epigenetic factors. Epigenetics refers to the regulation of DNA transcription without alteration of the original sequence and is controlled by DNA methylation, histone modifications and non-coding RNAs and can be transmitted through generations. A number of clinical and preclinical studies suggest that epigenetic mechanisms could play an important role in the pathogenesis and treatment of major depression. So far, most studies investigated genes within the hypothalamicpituitary- adrenal (HPA) axis or the neurotrophin system. It is also of interest that current psychopharmacologic drugs including antidepressants, antipsychotics and mood stabilizers may exert some of their effects by inducing epigenetic changes. Most notably, epigenetic alterations are potentially reversible and accessibe for drug treatment, which lead to the development of novel classes of antidepressant drugs.
Export Options
About this article
Cite this article as:
Menke Andreas, Klengel Torsten and B. Binder Elisabeth, Epigenetics, Depression and Antidepressant Treatment, Current Pharmaceutical Design 2012; 18 (36) . https://dx.doi.org/10.2174/138161212803523590
DOI https://dx.doi.org/10.2174/138161212803523590 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The HOX Gene Network as a Potential Target for Cancer Therapy
Current Cancer Therapy Reviews Metallothioneins and Synthetic Metal Chelators as Potential Therapeutic Agents for Removal of Aberrant Metal Ions from Metal-Aβ Species
Mini-Reviews in Medicinal Chemistry Immunophilins: Structures, Mechanisms and Ligands
Current Molecular Pharmacology The Weal and Woe of Costimulation in the Adoptive Therapy of Cancer with Chimeric Antigen Receptor (CAR)-Redirected T Cells
Current Molecular Medicine ACE2-Ang-(1-7)-Mas Axis in Brain: A Potential Target for Prevention and Treatment of Ischemic Stroke
Current Neuropharmacology Central Nervous System Agents Used as Trypanosoma cruzi Infection Chemotherapy: Phenothiazines and Related Compounds
Current Medicinal Chemistry - Anti-Infective Agents Acetylcholinesterase Inhibitors and Drugs Acting on Muscarinic Receptors- Potential Crosstalk of Cholinergic Mechanisms During Pharmacological Treatment
Current Neuropharmacology Regression of Oxidative Stress by Targeting eNOS and Nrf2/ARE Signaling: A Guided Drug Target for Cardiovascular Diseases
Current Topics in Medicinal Chemistry Acanthamoeba Keratitis: Current Status and Urgent Research Priorities
Current Medicinal Chemistry Carbon Nanotubes: An Emerging Drug Delivery Carrier in Cancer Therapeutics
Current Drug Delivery Anticancer Actions of Omega-3 Fatty Acids - Current State and Future Perspectives
Anti-Cancer Agents in Medicinal Chemistry On the Nature of the Tumor-Initiating Cell
Current Stem Cell Research & Therapy RECKing MMP: Relevance of Reversion-inducing Cysteine-rich Protein with Kazal Motifs as a Prognostic Marker and Therapeutic Target for Cancer (A Review)
Anti-Cancer Agents in Medicinal Chemistry Peptides for Therapy and Diagnosis of Alzheimer's Disease
Current Pharmaceutical Design SYNTHESIS AND APPLICATIONS OF Fe3O4/SiO2 CORE-SHELL MATERIALS
Current Pharmaceutical Design Biological Activity and Delivery of Peptide Nucleic Acids (PNA)-DNA Chimeras for Transcription Factor Decoy (TFD) Pharmacotherapy
Current Medicinal Chemistry Lopinavir/Ritonavir Treatment Induces Oxidative Stress and Caspaseindependent Apoptosis in Human Glioblastoma U-87 MG Cell Line
Current HIV Research Nitric Oxide Mimetic Molecules as Therapeutic Agents in Alzheimers Disease
Current Alzheimer Research Nanocarriers Conjugated with Cell Penetrating Peptides: New Trojan Horses by Modern Ulysses
Current Pharmaceutical Biotechnology Betulin-Betulinic Acid Natural Product Based Analogs as Anti-Cancer Agents
Anti-Cancer Agents in Medicinal Chemistry